创伤来源的细胞外囊泡足以诱导内皮功能障碍与凝血病
研究将严重创伤/失血性休克患者(ISS 32±6)与轻微创伤患者(ISS 8±3)血浆经超速离心富集的细胞外囊泡(EVs)输入未受伤的C57BL/6J小鼠,在异氟烷麻醉下按1×10^9至1×10^10 EV/100 μL/只给药,30分钟后检测凝血与内皮损伤指标。与接受轻微创伤患者EVs的小鼠相比,创伤/失血性休克EV组血浆凝血酶-抗凝血酶复合物(TAT)和syndecan-1显著升高,支气管肺泡灌洗液蛋白和肺组织病理损伤更重,肺组织血管内纤维蛋白沉积增强。初步概念验证实验中,较低浓度(5×10^6至3.1×10^9/100 μL/只)输入后30分钟TAT与syndecan-1无显著差异,但肺血管通透性、组织病理损伤显著升高并见血管内纤维蛋白沉积。作者认为创伤诱导的EVs可能成为新的治疗靶点。
要点
- 严重创伤/失血性休克患者(ISS 32±6)来源EVs按1×10^9至1×10^10 EV/100 μL/只输入正常小鼠,30分钟后血浆TAT和syndecan-1较轻微创伤患者(ISS 8±3)EV组显著升高。
- 同一高浓度实验中,创伤/失血性休克EV组支气管肺泡灌洗液蛋白和肺组织病理损伤更高,肺组织血管内纤维蛋白沉积增强。
- 初步概念验证实验用5×10^6至3.1×10^9/100 μL/只的EVs,输入后30分钟TAT与syndecan-1较PBS组无显著差异,但肺血管通透性和组织病理损伤显著升高并见血管内纤维蛋白沉积。
- 作者认为创伤/失血性休克导致EVs全身释放,可诱导内皮病(syndecan-1升高、通透性增加)和凝血病(TAT升高、血管内纤维蛋白沉积)。
- 作者提出靶向创伤诱导的EVs可能代表一种新的治疗策略。
适用人群与场景
- 严重创伤/失血性休克患者(初步实验ISS 34±7;后续实验ISS 32±6)与轻微创伤患者(ISS 8±3)的血浆EVs供体。
- 接受EVs输入的对象为未受伤的naive C57BL/6J小鼠,在异氟烷麻醉下进行。
处置流程与药物剂量
- EVs经超速离心从患者血浆中富集,并鉴定大小和数量。
- 初步概念验证实验:EVs按5×10^6至3.1×10^9/100 μL/只输入小鼠,与PBS对照比较。
- 后续实验:EVs按1×10^9至1×10^10 EV/100 μL/只输入小鼠,比较创伤/失血性休克EV组与轻微创伤EV组。
- 输入30分钟后处死小鼠,采血用ELISA检测凝血酶-抗凝血酶复合物(TAT)和syndecan-1,取肺组织行病理检查并用von Willebrand因子和纤维蛋白共染识别血管内凝血,取支气管肺泡灌洗液测蛋白作为内皮通透性指标。
研究设计与关键结果
- 研究类型:采用 adoptive transfer 实验,将患者血浆富集的EVs输入naive C57BL/6J小鼠。
- 初步概念验证实验:严重创伤/失血性休克患者(ISS 34±7)EVs按5×10^6至3.1×10^9/100 μL/只输入,30分钟后TAT和syndecan-1水平与PBS对照组无显著差异。
- 初步概念验证实验:同一实验中,EV组肺血管通透性和组织病理损伤显著高于PBS组,肺组织见血管内纤维蛋白沉积。
- 后续实验:创伤/失血性休克患者(ISS 32±6)EVs按1×10^9至1×10^10 EV/100 μL/只输入,30分钟后血浆TAT和syndecan-1水平显著高于接受轻微创伤患者(ISS 8±3)EVs的小鼠。
- 后续实验:创伤/失血性休克EV组支气管肺泡灌洗液蛋白和肺组织病理损伤高于轻微创伤EV组,肺组织血管内纤维蛋白沉积增强。
- 数据以mean±SD表示,P<0.05为显著,采用t检验。
证据类型、等级与局限
- 证据类型:动物实验(小鼠 adoptive transfer 实验)。
- 局限:原文未报告局限性
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Although a number of studies have demonstrated increased release of extracellular vesicles (EVs) and changes in their origin differentials after trauma, the biologic significance of EVs is not well understood. We hypothesized that EVs released after trauma/hemorrhagic shock (HS) contribute to endotheliopathy and coagulopathy. To test this hypothesis, adoptive transfer experiments were performed to determine whether EVs derived from severely injured patients in shock were sufficient to induce endothelial dysfunction and coagulopathy. Methods: Total EVs were enriched from plasma of severely injured trauma/HS patients or minimally injured patients by ultracentrifugation and characterized for size and numbers. Under isoflurane anesthesia, noninjured naive C57BL/6J mice were administered EVs at varying concentrations and compared with mice receiving equal volume vehicle (phosphate-buffered saline (PBS)) or to mice receiving EVs from minimally injured patients. Thirty minutes after injection, mice were sacrificed, and blood was collected for thrombin generation (thrombin-antithrombin, thrombin-antithrombin complex [TAT] assay) and syndecan-1 by enzyme-linked immunoabsorbent assay (ELISA). Lungs were harvested for examination of histopathologic injury and costained with von Willebrand factor and fibrin to identify intravascular coagulation. Bronchial alveolar lavage fluid was aspirated from lungs for protein measurement as an indicator of the endothelial permeability. Data are presented as mean ± SD, P < 0.05 was considered significant, and t test was used. Results: An initial proof-of-concept experiment was performed in naive mice receiving EVs purified from severely injured trauma/HS patients (Injury Severity Score [ISS], 34 ± 7) at different concentrations (5 × 106 to 3.1 × 109/100 μL/mouse) and compared with PBS (control) mice. Neither TAT nor syndecan-1 levels were significantly different between groups at 30 minutes after EV infusion. However, lung vascular permeability and histopathologic injury were significantly higher in the EV group, and lung tissues demonstrated intravascular fibrin deposition. Based on these data, EVs from severely injured trauma/HS patients (ISS, 32 ± 6) or EVs from minimally injured patients (ISS, 8 ± 3) were administered to naive mice at higher concentrations (1 × 109 to 1 × 1010 EV/100 μL/mouse). Compared with mice receiving EVs from minimally injured patients, plasma TAT and syndecan-1 levels were significantly higher in the trauma/HS EV group. Similarly, bronchial alveolar lavage protein and lung histopathologic injury were higher in the trauma/HS EV group, and lung tissues demonstrated enhanced intravascular fibrin deposition. Conclusion: These data demonstrate that trauma/HS results in the systemic release of EVs, which are capable of inducing endotheliopathy as demonstrated by elevated syndecan-1 and increased permeability and coagulopathy as demonstrated by increased TAT and intravascular fibrin deposition. Targeting trauma-induced EVs may represent a novel therapeutic strategy.
参考来源
- Zeineddin A, Wu F, Dong JF, et al. TRAUMA-DERIVED EXTRACELLULAR VESICLES ARE SUFFICIENT TO INDUCE ENDOTHELIAL DYSFUNCTION AND COAGULOPATHY. Shock. 2022. PMID: 35984759. doi:10.1097/SHK.0000000000001950
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。